Histone deacetylase inhibitors for cancer therapy

Tae You Kim, Yung Jue Bang, Keith D Robertson

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The epigenome of cancer cells is determined by DNA methylation and an array of post-translational modifications of the core histones. Epigenetic abnormalities are commonly found in human tumors and importantly, they can be reversed by pharmacologic inhibitors. Histone deacetylase inhibitors (HDACIs) represent one of the most promising epigenetic treatments for cancer. HDACIs have emerged as promising targets for cancer therapy because they reactivate the transcription of multiple genes that are silenced in human tumors and they show pleiotropic anti-tumor effects selectively in cancer cells. HDACIs are well-tolerated and several show promising anti-tumor activity. While gene transcription has been considered to be the major target of HDACIs, inhibition of acetylation of non-histone proteins is now emerging as a novel basis for their anti-tumor effects. In this review, we discuss new insights into the molecular mechanism of HDACIs, their current status of clinical development, and possible future uses in cancer therapy.

Original languageEnglish (US)
Pages (from-to)14-23
Number of pages10
JournalEpigenetics
Volume1
Issue number1
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Neoplasms
Therapeutics
Epigenomics
DNA Methylation
Post Translational Protein Processing
Acetylation
Oligonucleotide Array Sequence Analysis
Histones
Genes

Keywords

  • Cancer
  • Chromatin
  • Epigenetics
  • Histone deacetylase
  • Histone deacetylase inhibitor
  • Methylation
  • Transcription

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Medicine(all)

Cite this

Histone deacetylase inhibitors for cancer therapy. / Kim, Tae You; Bang, Yung Jue; Robertson, Keith D.

In: Epigenetics, Vol. 1, No. 1, 2006, p. 14-23.

Research output: Contribution to journalArticle

Kim, Tae You ; Bang, Yung Jue ; Robertson, Keith D. / Histone deacetylase inhibitors for cancer therapy. In: Epigenetics. 2006 ; Vol. 1, No. 1. pp. 14-23.
@article{de0f119cb87243f5acaf93279bd1fc22,
title = "Histone deacetylase inhibitors for cancer therapy",
abstract = "The epigenome of cancer cells is determined by DNA methylation and an array of post-translational modifications of the core histones. Epigenetic abnormalities are commonly found in human tumors and importantly, they can be reversed by pharmacologic inhibitors. Histone deacetylase inhibitors (HDACIs) represent one of the most promising epigenetic treatments for cancer. HDACIs have emerged as promising targets for cancer therapy because they reactivate the transcription of multiple genes that are silenced in human tumors and they show pleiotropic anti-tumor effects selectively in cancer cells. HDACIs are well-tolerated and several show promising anti-tumor activity. While gene transcription has been considered to be the major target of HDACIs, inhibition of acetylation of non-histone proteins is now emerging as a novel basis for their anti-tumor effects. In this review, we discuss new insights into the molecular mechanism of HDACIs, their current status of clinical development, and possible future uses in cancer therapy.",
keywords = "Cancer, Chromatin, Epigenetics, Histone deacetylase, Histone deacetylase inhibitor, Methylation, Transcription",
author = "Kim, {Tae You} and Bang, {Yung Jue} and Robertson, {Keith D}",
year = "2006",
doi = "10.4161/epi.1.1.2644",
language = "English (US)",
volume = "1",
pages = "14--23",
journal = "Epigenetics",
issn = "1559-2294",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Histone deacetylase inhibitors for cancer therapy

AU - Kim, Tae You

AU - Bang, Yung Jue

AU - Robertson, Keith D

PY - 2006

Y1 - 2006

N2 - The epigenome of cancer cells is determined by DNA methylation and an array of post-translational modifications of the core histones. Epigenetic abnormalities are commonly found in human tumors and importantly, they can be reversed by pharmacologic inhibitors. Histone deacetylase inhibitors (HDACIs) represent one of the most promising epigenetic treatments for cancer. HDACIs have emerged as promising targets for cancer therapy because they reactivate the transcription of multiple genes that are silenced in human tumors and they show pleiotropic anti-tumor effects selectively in cancer cells. HDACIs are well-tolerated and several show promising anti-tumor activity. While gene transcription has been considered to be the major target of HDACIs, inhibition of acetylation of non-histone proteins is now emerging as a novel basis for their anti-tumor effects. In this review, we discuss new insights into the molecular mechanism of HDACIs, their current status of clinical development, and possible future uses in cancer therapy.

AB - The epigenome of cancer cells is determined by DNA methylation and an array of post-translational modifications of the core histones. Epigenetic abnormalities are commonly found in human tumors and importantly, they can be reversed by pharmacologic inhibitors. Histone deacetylase inhibitors (HDACIs) represent one of the most promising epigenetic treatments for cancer. HDACIs have emerged as promising targets for cancer therapy because they reactivate the transcription of multiple genes that are silenced in human tumors and they show pleiotropic anti-tumor effects selectively in cancer cells. HDACIs are well-tolerated and several show promising anti-tumor activity. While gene transcription has been considered to be the major target of HDACIs, inhibition of acetylation of non-histone proteins is now emerging as a novel basis for their anti-tumor effects. In this review, we discuss new insights into the molecular mechanism of HDACIs, their current status of clinical development, and possible future uses in cancer therapy.

KW - Cancer

KW - Chromatin

KW - Epigenetics

KW - Histone deacetylase

KW - Histone deacetylase inhibitor

KW - Methylation

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=33846261713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846261713&partnerID=8YFLogxK

U2 - 10.4161/epi.1.1.2644

DO - 10.4161/epi.1.1.2644

M3 - Article

C2 - 17998811

AN - SCOPUS:33846261713

VL - 1

SP - 14

EP - 23

JO - Epigenetics

JF - Epigenetics

SN - 1559-2294

IS - 1

ER -